These data from both in vitro and in vivo studies define a role for a signaling axis involving hyperactive IFN signaling and decreased Wnt signaling in cardiogenic defects in DS, while also revealing avenues for potential therapeutics. This evidence concerns the gene IFNA1 and Dravet syndrome.